Paperonium

← Back to the plain-language case

Abstract and Introduction state the reverse of the paper's own Schwann cell depletion result

Sci Adv (2023) · doi:10.1126/sciadv.add6995 · PMC9891701

Summary

The Abstract states that "Depletion of pancreatic-specific TASc promoted the tumorigenesis of PDAC tumors", and the Introduction repeats it. (TASc are tumor-associated nonmyelinating Schwann cells.) The paper's only pancreas-specific depletion is intrapancreatic AAV8-GFAP-DTA in KPC mice. For that experiment the Results report improved survival (Fig. 2C; log-rank; n = 8, 12 and 13 mice), fewer PanIN 2/3 lesions and inhibited tumor growth (Fig. 2D–G). The Fig. 2 title reads "Depletion of TASc attenuates pancreatic cancer tumorigenesis". The main text contains 17 statements (14 sentences, one Results subsection heading and two figure titles) that state a direction for the effect of depleting, inhibiting or targeting TASc (or TASc-expressed PVT1) on tumors. Fifteen say depletion is antitumor. Only the Abstract and Introduction sentences say it is protumor. The data, statistics and the paper's central thesis are unaffected. Still, the Abstract, the paper's own summary of its findings, reverses the direction of its headline in vivo result, and no correction has been issued.

What the paper reports

The two sentences that state the depletion result as protumor:

Depletion of pancreatic-specific TASc promoted the tumorigenesis of PDAC tumors.

Abstract, sentence 4

Depletion of TASc promoted the tumorigenesis of PDAC.

Introduction, final (third) paragraph

The same experiment as described in the Results and in the Fig. 2 legend:

TASc promotes PDAC tumorigenesis

Results, subsection heading

KPC mice given AAV8-GFAP-DTA exhibited improved survival time compared to control group (Fig. 2C). Upon AAV8-GFAP-DTA–mediated Schwann cell depletion, KPC pancreases exhibited increased percentage of PanIN 1, reduced PanIN 2/3, and inhibited tumor growth (Fig. 2, D to G).

Results, "TASc promotes PDAC tumorigenesis", paragraph 1

Depletion of TASc attenuates pancreatic cancer tumorigenesis.

Fig. 2 title

Log-rank test; n = 8, 12, and 13 mice, respectively.

Fig. 2 legend, panel C (WT, AAV8-GFAP-Blank and AAV8-GFAP-DTA KPC mice)

Error bars, SDs; n = 12 and 13 animals, respectively; Student’s t test.

Fig. 2 legend, panel G (tumor volumes at 22 weeks)

The paper's own summary of the add-back experiment in the same subsection points the same way:

Together, these results suggested that the presence of TASc in PDAC facilitates tumorigenesis and resistance to immunotherapy.

Results, "TASc promotes PDAC tumorigenesis", paragraph 2, last sentence

So do the pharmacological depletion with fluorocitrate (FC), the Discussion, and a later sentence of the same Abstract:

Furthermore, depletion of TASc in PDAC may profoundly diminish tumor growth and improve the infiltration and cytotoxicity of CD8+ T cells.

Results, "Targeting TASc by fluorocitrate sensitizes PDAC to immunotherapy", last sentence

Depletion of TASc-expressed Pvt1 or TASc using FC restored the immunoresistant metabolic microenvironment and improved the antitumor effects of immune checkpoint inhibitors.

Discussion, paragraph 2

Furthermore, depletion of TASc using a small-molecule inhibitor effectively sensitized PDAC to immunotherapy, signifying the important roles of TASc in PDAC immune resistance.

Abstract, last sentence

Each quotation was checked character for character against the article as archived in PubMed Central (src/show.py PMC9891701 --grep), and the key sentences also against the publisher's typeset PDF (see Status).

What the paper's own numbers show

Method. No quantity can be recomputed, because the error is in the stated direction of an effect. The tumor volumes and survival curves appear only as plotted data in Fig. 2, and the text and figure title state their direction explicitly. recompute.py.txt therefore holds a hand-curated list of every statement (sentence, Results subsection heading or figure title) outside Materials and Methods that states a direction for the effect of depleting, inhibiting or targeting TASc, or TASc-expressed PVT1, on tumor growth, tumorigenesis, survival or response to immunotherapy. To build it, every sentence of the Abstract, Introduction, Results and Discussion, every Results subsection heading and every figure title was read. A statement was included when its subject is the removal or inhibition of TASc (by AAV8-GFAP-DTA, by fluorocitrate, by "a small-molecule" agent, or by targeting in general) or of TASc-expressed PVT1, and it states a direction for one of those outcomes. Statements left out were: those about the presence, rather than the removal, of TASc or PVT1 (such as the heading "TASc promotes PDAC tumorigenesis"); deletions of PVT1 nucleotides, RAF1 or TDO2; immune-cell or TASc-abundance readouts only; the cytotoxicity, safety or specificity of FC; and sentences calling TASc a therapeutic target without stating a tumor outcome. The script checks each listed statement verbatim against the archived text and confirms its section, labels each with the direction it states, and tallies them. Run with the publisher's PDF and supplement as text (instructions in the script header), it also checks those. It prints every number below.

Quantity Location Reported Recomputed from the paper's own text
Effect of depleting pancreatic TASc on tumorigenesis Abstract, sentence 4 "promoted the tumorigenesis" Opposite: depletion attenuates tumorigenesis (Results; Fig. 2 title; fig. S4 title)
Same Introduction, final paragraph "promoted the tumorigenesis" Opposite, as above
Survival after AAV8-GFAP-DTA depletion Results; Fig. 2C (log-rank; n = 8 WT, 12 Blank, 13 DTA) "improved survival time compared to control group" Depletion is antitumor
PanIN grade and tumor growth after depletion Results; Fig. 2D–G (Fig. 2F n = 8, 12, 13; Fig. 2G n = 12 vs 13) "reduced PanIN 2/3, and inhibited tumor growth" Depletion is antitumor
Fig. 2 title Fig. 2 legend "Depletion of TASc attenuates pancreatic cancer tumorigenesis." Depletion is antitumor
Directional statements on depleting, inhibiting or targeting TASc or TASc-expressed PVT1 Main text (Abstract, Introduction, Results incl. subsection headings, Discussion, figure titles) — 17 statements (14 sentences, 1 heading, 2 figure titles): 2 protumor (Abstract, Introduction), 15 antitumor
Statements about the AAV8-GFAP-DTA experiment only Main text — 5 statements: 2 protumor (Abstract, Introduction), 3 antitumor (Results ×2, Fig. 2 title)
Same, including the supplementary figure titles Main text + figs. S4, S13, S16 — 20 statements, 2 protumor, 18 antitumor (19 and 17 if the fig. S16 schematic is left out); DTA experiment 6 statements, 2 protumor, 4 antitumor
Fluorocitrate or small-molecule statements Main text — 7, all antitumor
PVT1-loss statements Main text — 3, all antitumor
Statements naming both PVT1 loss and FC Main text (Discussion) — 2, both antitumor
Sections that contain a protumor statement Main text — Abstract and Introduction only
Supplement sentences of the form "deplet… promot… tumorigen…" Supplementary Materials PDF — 0

The Abstract itself contains three depletion statements in opposite directions. Sentence 4 says depletion is protumor. The PVT1 sentence and the last sentence say depletion is antitumor.

A minor side observation that does not affect the finding: the Fig. 2G legend names three groups (WT, AAV8-GFAP-Blank, AAV8-GFAP-DTA) but gives n for only two ("n = 12 and 13 animals").

Figure

The Abstract and Introduction sentences beside the Results and Fig. 2 statements for the same depletion experiment

Figure 1. The left panel (orange) shows the two sentences, in the Abstract and the Introduction, that state the depletion result as protumor. The right panel (blue) shows what the paper reports for the same experiment, intrapancreatic AAV8-GFAP-DTA in KPC mice: the Results phrases for Fig. 2C and Fig. 2D–G, with sample sizes from the Fig. 2 legend, and the Fig. 2 title. The connector marks the conflict: one experiment, two opposite directions. All text is quoted from the paper. None of the paper's figures or data are reproduced.

Every directional statement on depleting or inhibiting TASc, by section

Figure 2. Each marker is one of the 17 main-text statements that state a direction for the effect of depleting, inhibiting or targeting TASc, or TASc-expressed PVT1, on tumors (inclusion rule under Method). Columns run in reading order from the Abstract to the Discussion, followed by the two figure titles. The Results FC column includes the subsection heading "Targeting TASc by fluorocitrate sensitizes PDAC to immunotherapy". The upper row holds statements that depletion promotes tumorigenesis. The lower row holds statements that it inhibits tumor growth or improves outcome. Marker shape gives the intervention: circles for AAV8-GFAP-DTA, squares for PVT1 loss, diamonds for fluorocitrate, triangles for sentences that name both PVT1 and FC. Markers in the same cell are stacked. Only the two orange markers, in the Abstract and the Introduction, sit in the upper row. Both concern the DTA experiment, whose three other statements all sit in the lower row. The supplementary titles of figs. S4, S13 and S16 (not drawn) would all sit in the lower row. Directions and locations come from recompute.py.txt.

Why it matters

Explanations considered

  1. The sentences refer to a different experiment or setting. This does not hold. "Pancreatic-specific" depletion matches only the intrapancreatic AAV8-GFAP-DTA delivery in KPC mice (Fig. 2, fig. S4). Every other statement about that experiment, in the Results, the Fig. 2 title and the fig. S4 title, reports an antitumor effect. The paper reports no subgroup, time point or model in which depletion accelerated tumors.
  2. "Tumorigenesis" is used in an unusual sense. This does not hold. The paper uses the word in its ordinary sense throughout, for example "TASc promotes PDAC tumorigenesis" and "Combining FC with the anti–PD-1 antibody significantly suppressed PDAC tumorigenesis".
  3. The increase in PanIN 1 lesions counts as "promoted". This does not hold. After depletion, the percentage of low-grade PanIN 1 rose while the share of high-grade PanIN 2/3 fell. The paper reports this shift in the same sentence as "inhibited tumor growth" and summarizes the panel under the title "Depletion of TASc attenuates pancreatic cancer tumorigenesis".
  4. The intended subject was TASc, not their depletion. "TASc promoted the tumorigenesis of PDAC", as in the Results heading, would be consistent with the data. So would "Depletion of TASc attenuated tumorigenesis", as in the Fig. 2 title. This explains how the wording could have arisen. It does not change the fact that the printed sentences state the opposite of the data.
  5. Conversion or archiving artifact. Ruled out. The publisher's typeset PDF in the PMC Open Access dataset (version 1, the only version; marked as the publisher's version, not an author manuscript) contains both sentences word for word. So does the Europe PMC full text. The conflict is in words ("promoted" against "attenuates"), not in symbols, signs or table cells that a conversion could alter.
  6. The supplement resolves it. It does not. The fig. S4 title ("Depletion of TASc inhibits PDAC tumorigenesis."), the fig. S13 title ("FC treatment sensitizes PDAC to immunotherapy.") and the title of the fig. S16 schematic ("Targeting tumor-associated non-myelinating Schwann cells improves anti-tumor immunity of immunotherapy-refractory pancreatic cancer.") all support the Results. The supplement contains no sentence saying depletion promotes tumorigenesis.

None of these explanations reconciles the Abstract and Introduction sentences with the paper's results.

Status

As of 2026-10-23:

Suggested correction

Reverse the direction in the two sentences so that they match the Results, the Fig. 2 title and the fig. S4 title:

No change to the data, figures, statistics or conclusions is needed. The Fig. 2G legend could also give the WT group size, since it currently gives n for two of its three groups.